Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03271372 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion pushed from Apr 3, 2026 to Jan 31, 2029v36
MinorPrimary completion date changed from estimate of Apr 30, 2026 to Apr 3, 2026v35
Minor4 versionsRe-verified since Sep 18, 2024, no change to tracked fieldsv31-v34
NotablePrimary completion date: Jul 1, 2025 to Apr 30, 2026Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 100 to confirmed 101 · Study sites: 10 to 9 · 1 morev30Show 4 more changesShow less
Trial status: Recruiting to Active, Not Recruiting
Enrollment target: estimated 100 to confirmed 101
Study sites: 10 to 9
Completion date: Jul 1, 2025 to Feb 18, 2029
MinorStudy sites: 11 to 10v29
Show 27 earlier versionsHide 27 earlier versions
MinorSite contacts updated at 3 of 11 sitesv28
MinorEligibility criteria expanded, about 21 wordsSecondary endpoints: details revised at 1 of 4 entries · Study description expanded, about 9 wordsv27Show 2 more changesShow less
Secondary endpoints: details revised at 1 of 4 entries
MinorPrimary and study completion dates: Aug 30, 2024 to Feb 25, 2025v20
MinorEligibility criteria shortened, about 15 wordsStudy description shortened, about 126 words · Site contacts updated at 3 of 11 sitesv19Show 2 more changesShow less
MinorPrimary and study completion dates: Sep 1, 2024 to Aug 30, 2024Interventions: Avelumab (Drug), Laboratory Biomarker Analysis (Other), Placebo Administration (Other) to Avelumab (Drug), Peripheral Blood Collection (Other), Placebo (Other) · Eligibility criteria expanded, about 13 words · Site contacts updated at 1 of 11 sites · 1 morev15Show 4 more changesShow less
MinorInterventions: Avelumab (Drug), Laboratory Biomarker Analysis (Other), Placebo (Other) to Avelumab (Drug), Laboratory Biomarker Analysis (Other), Placebo Administration (Other)Eligibility criteria shortened, about 23 words · Study sites revised (11) · Study description shortened, about 4 wordsv14Show 3 more changesShow less
MinorSecondary endpoints: details revised at 1 of 4 entriesv8
MinorStudy sites: 4 to 8v7
MinorStudy sites: 2 to 4v6
MinorStart date changed from estimate of Dec 30, 2017 to Dec 19, 2017Eligibility criteria expanded, about 644 words · Secondary endpoints revised (4)v5Show 2 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingSite details revised at 2 of 2 sitesv4Show 1 more changeShow less
Site details revised at 2 of 2 sites
NotableStart date: Oct 30, 2017 to Dec 30, 2017v3
NotableStart date: Sep 30, 2017 to Oct 30, 2017Eligibility criteria shortened, about 643 words · Secondary endpoints: details revised at 4 of 4 entries · Study description expanded, about 9 wordsv2Show 3 more changesShow less
Eligibility criteria shortened, about 643 words
Secondary endpoints: details revised at 4 of 4 entries
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.